Abstract
The breakpoint for resistance to vancomycin for Staphylococcus aureus is a minimum inhibitory concentration (MIC) of greater than 8 μg/mL (1). Isolation of the first strain of MRSA resistant to vancomycin (VRSA) Mu50 was made from a Japanese surgical patient with a wound infection who had failed with vancomycin therapy (2). A strain has been described that is heterogeneously resistant to vancomycin (Mu3 strain), and it was found to be susceptible to vancomycin (MIC 2 μg/mL by NCCLS criteria), but there were cells within the Mu3 population that resisted a vancomycin concentration of up to 9 μg/mL) (1). Most of the clinical S. aureus strains having reduced susceptibility to glycopeptide antibiotics are heterogeneous in their phenotypic resistance expression. The strains contain small subpopulations of cells that have different levels of glycopeptide resistance. They are designated hetero-resistant strains, and are defined by the population analysis (see below). MIC or paper disc susceptibility tests cannot detect heteroresistant strains. It would appear that heterogeneously resistant VRSA is a preliminary stage that allows development into full resistance upon further exposure to vancomycin. Therefore, it seems reasonable to include VRSA and hetero-VRSA as possible risk factors for vancomycin therapeutic failure in MRSA infection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, F., and Kobayashi, I. (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670–1673.
Hiramatsu K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., and Tenover, F. C. (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135–136.
Niitsuma, K. and Saito, M. (1996) Vancomycin inhalation therapy a pharmacokinetic and clinical study of vancomycin. Antibiot. Chemother. 122, 123–135.
Torres, J. R., Sandres, C. V., and Lewis, A. C. (1979) Vancomycin concentration in human tissues: preliminary report. J. Antimicrob. Chemother. 5, 475–477.
Lorian, V. (1966) The gradient plate method, in Antibiotics and Chemotherapeutic Agents in Clinical and Laboratory Practice (Thomas, C. C., ed.), Springfield, IL, pp. 102–103.
Stranden, A. M., Roos, M., and Berger-Bach, B. (1996) Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus. Microbial. Drug Resistance 2, 201–207.
Lea, D. and Coulson, C. A. (1949) The distribution of the numbers of mutants in bacterial populations. J. Genet. 49, 264–285.
Hanaki H., Inaba, Y., Sasaki, K., and Hiramatsu, K. (1998) A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (Hetero-VRSA). Jpn. J. Antibiot. 51, 521–530.
Hanaki H., Ohkawa, S., Inaba, Y., Hashimoto, T., and Hiramatsu, K. (1998) Development of medium (Mu3) for detection of hetero-vancomycin resistant MRSA (hetero-VRSA). Program abstracts of the 38rd Intersci. Confer. Antimicrob. Agents Chemother. abst. C-132.
Riley S. and Toennies, G. (1960) Nutritional requirements for bacterial cell wall synthesis. Nutr. Cell Wall 84, 44–50.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 The Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Hanaki, H., Hiramatsu, K. (2001). Detection Methods of Glycopeptide-Resistant Staphylococcus aureus I. In: Gillespie, S.H. (eds) Antibiotic Resistence. Methods in Molecular Medicine™, vol 48. Humana Press. https://doi.org/10.1385/1-59259-077-2:85
Download citation
DOI: https://doi.org/10.1385/1-59259-077-2:85
Publisher Name: Humana Press
Print ISBN: 978-0-89603-777-9
Online ISBN: 978-1-59259-077-3
eBook Packages: Springer Protocols